<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165762</url>
  </required_header>
  <id_info>
    <org_study_id>SU-06232010-6408</org_study_id>
    <secondary_id>P01HL075462</secondary_id>
    <nct_id>NCT01165762</nct_id>
  </id_info>
  <brief_title>Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.</brief_title>
  <official_title>Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T-cell Transfusion in HLA Haplotype Match Living Donor Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Stanford Medical Center Program in Multi-Organ Transplantation and the Division of Bone
      marrow Transplantation are enrolling patients into a research study to determine if donor
      stem cells given after a living related one Haplotype match kidney transplantation will
      change the immune system such that immunosuppressive drugs can be completely withdrawn.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is for the recipients of a living related kidney transplant of one HLA
      haplotype to be withdrawn of immunosuppressive medication and become &quot;tolerant &quot;to their
      kidney graft. The recipient will receive a conditioning regimen composed of low dose
      radiation to the lymphoid tissue (total lymphoid irradiation, TLI) and anti-thymocyte
      globulin (ATG) at the time of transplant. They will then be infused with purified &quot;stem cell&quot;
      and T-cell from their kidney donors 2 weeks after the transplant to try to achieve mixed
      chimerism of their white blood cells with the donor (the recipient would have a mixture some
      of the with blood cells of the donor and theirs in their blood). The kidney donor has to
      provide peripheral stem cell 6-8 weeks before kidney donation. It is an outpatient procedure
      done using peripheral veins after treatment with G-CSF (filgrastim).Immunosuppressive
      medication will be decreased gradually and possibly stopped by 1 1/2 year after the
      transplantation if the recipient meets withdrawing criteria (persistence of mixed chimerism
      more than 18 months, no episode of rejection and no rejection on surveillance kidney biopsy).
      Potential candidates need to be approved for kidney transplant and available for close
      follow-up at Stanford University Medical Center.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long term freedom from transplant immunosuppressive drugs, safety, rate of infection, graft survival and patient survival.</measure>
    <time_frame>5 years and indefinitely if possible</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>ESRD</condition>
  <arm_group>
    <arm_group_label>Immune Tolerance, Kidney transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction of immune tolerance in Haplotype matched living donor kidney transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immune Tolerance</intervention_name>
    <description>Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.
The IDE used in this study is the column used for hematopoietic cell sorting.</description>
    <arm_group_label>Immune Tolerance, Kidney transplantation</arm_group_label>
    <other_name>Kidney transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All consenting adult (&gt; 18 years of age) living donor renal transplant recipients at
             Stanford University Medical Center who have a one haplotype match donor.

          2. Patients who agree to participate in the study and sign an Informed Consent.

          3. Patients who have no known contraindication to administration of rabbit ATG or
             radiation.

          4. Males and females of reproductive potential who agree to practice a reliable form of
             contraception for at least 24 months posttransplant.

          5. ABO compatible.

        Exclusion Criteria:

          1. Previous treatment with rabbit ATG or a known allergy to rabbit proteins.

          2. History of malignancy with the exception of non-melanoma skin malignancies.

          3. Pregnant women or nursing mothers.

          4. Serological evidence of HIV, Hepatitis B or Hepatitis C infection.

          5. Seronegative for Epstein-Barr virus, if donor is seropositive.

          6. Leukopenia (with a white blood cell count &lt; 3000/mm3) or thrombocytopenia (with a
             platelet count &lt; 100,000/mm3).

          7. Panel Reactive Antibody greater than 20% or demonstration of donor specific antibody
             (DSA)

          8. Prior organ transplantation

          9. High risk of primary kidney disease recurrence (i.e.FSGS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan Busque</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asha Shori, CCRP</last_name>
    <phone>(650) 736-0245</phone>
    <email>ashas@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asha Shori, CCRP</last_name>
      <phone>650-736-0245</phone>
      <email>ashas@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>John D Scandling</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Judith Anne Shizuru</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr. Marc L. Melcher</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard T. Hoppe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Lowsky</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie M. Yabu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel Md Strober</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Busque</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Millan MT, Shizuru JA, Hoppe RT, Lowsky R, Engleman EG, Strober S. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med. 2008 Jan 24;358(4):362-8. doi: 10.1056/NEJMoa074191.</citation>
    <PMID>18216356</PMID>
  </reference>
  <reference>
    <citation>Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney transplantation. N Engl J Med. 2011 Oct 6;365(14):1359-60. doi: 10.1056/NEJMc1107841.</citation>
    <PMID>21991976</PMID>
  </reference>
  <reference>
    <citation>Scandling JD, Busque S, Dejbakhsh-Jones S, Benike C, Sarwal M, Millan MT, Shizuru JA, Lowsky R, Engleman EG, Strober S. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. Am J Transplant. 2012 May;12(5):1133-45. doi: 10.1111/j.1600-6143.2012.03992.x. Epub 2012 Mar 8.</citation>
    <PMID>22405058</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2010</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Stephan Busque</investigator_full_name>
    <investigator_title>Professor of Surgery, Abdominal Transplantation, Stanford University Medical Center</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

